We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

An Open-label Study Investigating the Disposition and QT/QTc Interval Effects of 400 mg [14C]-Iniparib(3.7 MBq, 100 µCi)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01161836
First Posted: July 14, 2010
Last Update Posted: September 24, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Sanofi
  Purpose

This is a Phase 1, multi-center, open-label study.

During Segment 1, patients are administered a single IV administration of [14C]-iniparib.

During Segment 2, patients are administered iniparib with or without additional chemotherapy. Acceptable chemotherapy regimens is limited to those for which previous experience with iniparib exists.


Condition Intervention Phase
Advanced Solid Tumors Drug: Iniparib Phase 1

Access to an investigational treatment associated with this study is no longer available outside the clinical trial.   More info ...

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: An Open-label Study Investigating the Disposition and QT/QTc Interval Effects of 400 mg [14C]-Iniparib(3.7 MBq, 100 µCi) Administered at Cycle 1 as a 60-minute Intravenous Infusion to Patients With Advanced Solid Tumors Followed by Extended Treatment With BSI-201 With or Without Additional Chemotherapy

Further study details as provided by Sanofi:

Primary Outcome Measures:
  • The excretion balance and systemic exposure of radioactivity after intravenous (IV) administration of [14C]-iniparib [ Time Frame: Up to 35 days ]
  • The pharmacokinetics of iniparib, iodo-amino-benzamide (IABM) and iodo-amino-benzoic acid (IABA) and their contribution to overall exposure of radioactivity [ Time Frame: up to 35 days ]
  • The effects of iniparib on changes in the ECG with special focus on the QTcF interval duration [ Time Frame: 96 hours ]
  • The metabolic pathways of iniparib and identify the chemical structures of the main metabolites. [ Time Frame: Up to 35 days ]

Secondary Outcome Measures:
  • The clinical and biological tolerability of iniparib. [ Time Frame: During treatment and until 30 days post treatment ]

Enrollment: 7
Study Start Date: July 2010
Study Completion Date: June 2011
Primary Completion Date: February 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: iniparib

Segment 1: 400 mg [14C]-iniparib single administration

Segment 2: Iniparib, 5.6mg/kg, extension treatment with or without additional chemotherapy

Drug: Iniparib

Solution for infusion

60-minute intravenous infusion

Other Names:
  • SAR240550
  • BSI-201

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Male or female patients with advanced solid tumors that are refractory to standard treatment or for which no standard treatment exists; patients must be at least 18 years old.

Additional criteria are also required and should be evaluated by the research staff.

  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01161836


Locations
United States, Washington
Northwest Medical Specialties
Tacoma, Washington, United States, 98405
Sponsors and Collaborators
Sanofi
Investigators
Study Director: Clinical Sciences & Operations Sanofi
  More Information

Responsible Party: Sanofi
ClinicalTrials.gov Identifier: NCT01161836     History of Changes
Other Study ID Numbers: BEX11505
20100109 ( Other Identifier: BiPar )
First Submitted: July 12, 2010
First Posted: July 14, 2010
Last Update Posted: September 24, 2013
Last Verified: September 2013

Additional relevant MeSH terms:
Iniparib
Poly(ADP-ribose) Polymerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents